Alcon/$ALC
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Alcon
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Ticker
$ALC
Sector
Primary listing
NYSE
Employees
25,000
Headquarters
Geneva, Switzerland
Website
Alcon Metrics
BasicAdvanced
$39B
38.20
$2.10
0.69
$0.22
0.27%
Price and volume
Market cap
$39B
Beta
0.69
52-week high
$99.20
52-week low
$71.55
Average daily volume
2.1M
Dividend rate
$0.22
Financial strength
Current ratio
2.118
Quick ratio
1.15
Long term debt to equity
20.785
Total debt to equity
23.723
Dividend payout ratio (TTM)
15.85%
Interest coverage (TTM)
6.52%
Profitability
EBITDA (TTM)
2,510
Gross margin (TTM)
55.57%
Net profit margin (TTM)
10.28%
Operating margin (TTM)
12.73%
Effective tax rate (TTM)
15.90%
Revenue per employee (TTM)
$410,000
Management effectiveness
Return on assets (TTM)
2.62%
Return on equity (TTM)
4.82%
Valuation
Price to earnings (TTM)
38.196
Price to revenue (TTM)
3.895
Price to book
1.42
Price to tangible book (TTM)
8.6
Price to free cash flow (TTM)
28.745
Free cash flow yield (TTM)
3.48%
Free cash flow per share (TTM)
2.79
Dividend yield (TTM)
0.27%
Forward dividend yield
0.27%
Growth
Revenue change (TTM)
4.34%
Earnings per share change (TTM)
-10.23%
3-year revenue growth (CAGR)
5.41%
3-year earnings per share growth (CAGR)
22.23%
3-year dividend per share growth (CAGR)
12.09%
What the Analysts think about Alcon
Analyst ratings (Buy, Hold, Sell) for Alcon stock.
Alcon Financial Performance
Revenues and expenses
Alcon Earnings Performance
Company profitability
Alcon News
AllArticlesVideos
STAAR Surgical Sets the Record Straight Regarding its Robust Go-Shop Process
Business Wire·13 hours ago
Broadwood Partners Comments on STAAR Surgical Board Dissent on the Revised Sale to Alcon
Business Wire·16 hours ago
STAAR Surgical's Top Investors Reject Sweetened Alcon Offer, Cite Flawed Sale Process
Benzinga·1 day ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Alcon stock?
Alcon (ALC) has a market cap of $39B as of December 12, 2025.
What is the P/E ratio for Alcon stock?
The price to earnings (P/E) ratio for Alcon (ALC) stock is 38.2 as of December 12, 2025.
Does Alcon stock pay dividends?
Yes, the Alcon (ALC) stock pays dividends to shareholders. As of December 12, 2025, the dividend rate is $0.21783 and the yield is 0.27%. Alcon has a payout ratio of 15.85% on a trailing twelve-month basis.
When is the next Alcon dividend payment date?
The next Alcon (ALC) dividend payment date is unconfirmed.
What is the beta indicator for Alcon?
Alcon (ALC) has a beta rating of 0.69. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.